Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11411256 | 0.95 | CTSL (0.56) | CTSLPTGER4CTSSFOLH1SIRT2 | |
| SCHEMBL5929274 | 0.94 | CTSL (0.73) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL10787733 | 0.94 | NPY4R (0.61) | CTSLCTSB | |
| SCHEMBL10787739 | 0.94 | NPY4R (0.61) | CTSLCTSB | |
| SCHEMBL29473451 | 0.93 | CTSL (0.59) | CTSLPTGER4CTSBCTSSCTSK | |
| SCHEMBL8595664 | 0.93 | CTSL (0.56) | CTSLPTGER4CTSBCTSSCTSK | |
| SCHEMBL6768020 | 0.93 | FOLH1 (0.59) | CTSLCTSSFOLH1SIRT2SIRT1 | |
| SCHEMBL5145708 | 0.93 | FOLH1 (0.59) | CTSLCTSSFOLH1SIRT2SIRT1 | |
| SCHEMBL631840 | 0.93 | FOLH1 (0.59) | CTSLCTSSFOLH1SIRT2SIRT1 | |
| SCHEMBL19784348 | 0.92 | CTSL (0.66) | CTSLPTGER4CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177947-A1 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-09 | — | — | US | claimed |
| EP-1833982-B1 | HEMOSTASIS ASSAY | STICHTING KATHOLIEKE UNIV (NL) | 2010-12-01 | — | — | EP | claimed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025055943-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025055942-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4511367-A1 | FAP INHIBITORS | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240279586-A1 | Biological Indicator with Adjusted Resistance Characteristics | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-08-22 | — | — | US | disclosed |
| EP-3585447-B1 | PROCESS FOR THE PREPARATION OF DOUBLE CROSSLINKED CORE-SHELL POLYMERIC NANOPARTICLES FOR MULTIMODAL IMAGING AND THERANOSTIC APPLICATIONS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2024-07-24 | — | — | EP | disclosed |
| US-20220257604-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114728008-A | Compounds for identifying beta-lactamases and methods of use thereof | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| US-11311853-B2 | Process for the preparation of double crosslinked core-shell polymeric nanoparticles for multimodal imaging and theranostic applications | FONDAZIONE ISTITUTO ITALIANO Dl TECNOLOGIA (IT) | 2022-04-26 | — | — | US | disclosed |
| WO-2022034498-A1 | MOVING-FRONT STERILIZATION MONITORING DEVICES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-02-17 | — | — | WO | disclosed |
| US-10421725-B2 | Alkoxyamines for the treatment of cancers | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-24 | — | — | US | disclosed |
| US-20160115130-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-04-28 | — | — | US | disclosed |
| EP-3010881-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | Centre National de la Recherche Scientifique (FR) | 2016-04-27 | — | — | EP | disclosed |
| WO-2015001436-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-01-08 | — | — | WO | disclosed |
| EP-2816027-A1 | Alkoxyamines for the treatment of cancers | Centre National De La Recherche Scientifique (FR) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177947-A1 | Compounds to Identify Beta-Lactamases, and Methods of Use Thereof | GUSB, GLB1, MGAM | CTSL 85/4885PTGER4 3965/4885CTSB 168/4885 |
| US-20160115130-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | ERBB2, ALK, EGFR | CTSL 3927/4885PTGER4 1742/4885CTSB 1993/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | CTSL 154/4885PTGER4 3614/4885CTSB 86/4885 |
| US-10421725-B2 | Alkoxyamines for the treatment of cancers | ERBB2, ALK, EGFR | CTSL 3927/4885PTGER4 1742/4885CTSB 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.